Owner Investor / Financier Operator Developer
Merck & Co., Inc. (branded as MSD outside the United States and Canada) is a global biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of human prescription medicines, vaccines, and biologic therapies. The company’s portfolio and pipeline span major therapeutic areas including oncology, infectious diseases, vaccines, cardiometabolic conditions, and immunology.
Merck also operates a substantial animal health business (Merck Animal Health/MSD Animal Health), providing veterinary pharmaceuticals, vaccines, and health management solutions for companion and production animals. The company maintains a worldwide network of research, clinical development, and manufacturing sites supporting small-molecule, biologics, and vaccine production.
Note: Merck & Co., Inc. (MSD) is distinct from Merck KGaA, Darmstadt, Germany, which operates separately and uses different branding in North America.
Also known as Merck Group, Merck KGaA, Darmstadt, Germany, Merck KGaA, MSD, and Merck Sharp & Dohme.
chemXplore tracks 9 projects involving Merck, of which 3 are active.
Besides these 3, the record holds 6 completed projects.
Closest to start-up first.
The 6 that are completed, on hold or cancelled are in the record. See all 9 in chemXplore →
A $550 million R&D expansion adds automated robotics and AI to streamline clinical-sample analysis and support a broad clinical development pipeline.
Phase 3 intismeran combo improved recurrence‑free and distant metastasis‑free survival in resected stage IIB–IV melanoma; sac‑TMT and KEYNOTE‑C93 report pivotal endometrial cancer findings; >90 additional abstracts.
Remigromig met non-inferiority for mean BCVA change versus monthly ranibizumab at one year in DME; higher rates of PDR-related adverse events and discontinuations were reported.
Phase 2b trial met HiSCR50 at week 16 for two dosing regimens; HiSCR75 and DLQI showed numeric gains; safety comparable to placebo; results to inform Phase 3.
Exclusive global licence for a preclinical oral KRAS G12D (ON) molecular‑glue inhibitor; $400M upfront and $2.13B total potential; Merck to lead development and commercialization.
BLA for I‑DXd seeking accelerated approval in extensive‑stage SCLC withdrawn after FDA said Phase 2 data were insufficient; Phase 3 programmes continue.
Tri-specific Wnt-pathway agonist showed non-inferior BCVA gains vs ranibizumab at week 52; higher rates of PDR, vitreous hemorrhage and discontinuations observed.
FDA updates PAH therapy label to include HYPERION data showing a 76% reduction in clinical worsening when added to background therapy for patients diagnosed within 12 months.
active all projects
What each is building and closing, and the pipelines and grids between them, on one map.
